Abbott Laboratories (ABT)
Reasons to Retain ABT Stock in Your Portfolio Now
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
Is There More Upside For ABT Stock After A 10% Jump In A Week?
Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and $1.34, respectively.
Abbott Laboratories: Strong Q4 Results And Bullish Outlook
On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion for the three months ended December 31, 2024, up 7.2% year-on-year, driven by strong sales in the company's Medical Devices segment. Moreover, Abbott expects its revenue to grow by 7.5% to 8.5% in 2025, while its adjusted diluted EPS will be between $5.05 and $5.25, implying double-digit percentage growth year-over-year.
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
The outlook and technical action suggest Abbott Laboratories NYSE: ABT will lead healthcare names like Johnson & Johnson NYSE: JNJ higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.
Why Is Abbott Stock Trading Higher On Thursday?
On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
Two Contrarian Dividends With Triple-Digit Potential For Trump 2.0
Tariff Day has left us with Canada and Mexico in the crosshairs. With North American trade in focus, this may actually give a respite to stocks with supply chains elsewhere and light a fire under them.
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month. The company looks set up to deliver double-digit annual adjusted diluted EPS growth for the foreseeable future. Abbott Laboratories enjoys an AA- credit rating from S&P on a stable outlook.
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors.
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday.
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT ) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman & Chief Executive Officer Phil Boudreau - Executive Vice President, Finance & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Josh Jennings - TD Cowen David Roman - Goldman Sachs Joanne Wuensch - Citi Danielle Antalffy - UBS Matt Miksic - Barclays Operator Good morning and thank you for standing by. Welcome to Abbott's Fourth Quarter 2024 Earnings Conference Call.
Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics
The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
